generalized

Benin (Butocine) is an effective cytostatic drug used for the treatment of generalized carcinoma of the breast.

Dulozafone (F1933) has an anti- showed anticonvulsant activity in a brain amygdala ignition model and protected fully ignited rats from generalized seizures.

Topiramate (RWJ 17021) is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.

Harmaline hydrochloride (Harmidine hydrochloride) is a fluorescent indole alkaloid from the group of harmala alkaloids and beta-carbolines. It is the partially hydrogenated form of harmine.Harmaline produces a generalized tremor in normal rats by inducing rhythmic firing of inferior olivary neurons

Beclamide (Chlorakon) (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalized tonic-clonic seizures. It was not effective for absence seizures.

L-Pipecolic acid (L-Homoproline) is a breakdown product of lysine, accumulates in body fluids of infants with generalized genetic peroxisomal disorders, such as Zellweger syndrome, neonatal adrenoleukodystrophy.

N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.

Duloxetine D3 hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for the treatment of major depressive disorder and generalized anxiety disorder (GAD). Duloxetine D3 hydrochloride ((S)-Duloxetine D3 hydrochloride) is a deuterium-labeled Duloxetine hydrochloride.

Piragliatin, also known as RO4389620, is a glucokinase activator. Piragliatin greatly enhances glucose-induced pancreatic islet respiration and insulin release. Piragliatin lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus. Piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of β-cell function and through fasting restricted changes in glucose turnover.

Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA) primarily functioning as a sigma (σ) receptor agonist. It interacts effectively with sigma recognition sites, having a Ki value of 50 nM. Opipramol is applicable in the study of generalized anxiety disorder (GAD).

AZD6280 is a novel, subtype-selective GABAAα2 3 receptor positive modulators, used for treatment of generalized anxiety disorder.

Troriluzole is an orally active glutamate modulator with anticancer activity.Troriluzole enhances the expression of excitatory amino acid transporters located in glial cells and is used in the study of spinocerebellar ataxia, Alzheimer's disease, and generalized anxiety disorder (GAD).

Cognac oil, predominantly derived from wine lees, exhibits distinctive fatty acid compositions, characterized by high proportions of Palmitic acid (59.26%), Linoleic acid (11.92%), Myristic acid (8.97%), and Oleic acid (8.3%) among other fatty acids. Notably, the application of Cognac oil enhances the permeability of Rhodamine 6G (R6G) across various membranes, resulting in a generalized increase in permeation.

M-5011 is a non-steroidal anti-inflammatory drug and immunomodulator potentially for the treatment of inflammation and pain. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg kg. M-5011 partially inhibits the generalized bone loss a

Buspirone hydrochloride (Buspar) is a 5HT(1A) receptor agonist, used to treat generalized anxiety disorder (GAD).

Buspirone-d8 HCl (n-butyl-d8) is a deuterated compound of Buspirone HCl. Buspirone HCl has a CAS number of 33386-08-2. Buspirone is a 5HT(1A) receptor agonist, used to treat generalized anxiety disorder (GAD).

GYKI 52466 is an allosteric AMPA receptor antagonist. It selectively inhibits AMPA-induced inward currents (IC50 = 7.5 µM) over NMDA- or GABA-induced inward currents in primary rat hippocampal neurons at 50 µM but also inhibits kainate-induced inward currents in the same cells (IC50 = 11 µM).2 GYKI 52466 (10 µM) reduces the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) in the same cells. It increases the latency to seizure onset and reduces mortality in a rat model of generalized tonic-clonic seizures induced by 4-aminopyridine (4-AP) when administered at doses of 25 and 50 mg kg. GYKI 52466 (30 mg kg) prevents neuronal damage in the CA1 region of the hippocampus in a rat model of global ischemia-reperfusion injury induced by four-vessel occlusion.

D3017, the primary alcohol metabolite of D2624, is orally active and possesses anticonvulsant properties. It has an ED50 value of 1.5 mg kg in mice, and is applicable for studies on severe generalized tonic-clonic (grand mal) seizures and complex partial epilepsy.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

ACT-709478 is a potent, selective T-type calcium channel blocker that is orally active and capable of penetrating the brain. It is currently utilized in research focusing on generalized epilepsies[1].

Duloxetine-d7 is a deuterated compound of Duloxetine. Duloxetine has a CAS number of 116539-59-4. Duloxetine is an inhibitor of serotonin-norepinephrine reuptake(Ki of 4.6 nM),with treatment of major depressive disorder and generalized anxiety disorder.

Siramesine Fumarate, a sigma receptor agonist, is used potentially for the treatment of generalized anxiety disorder.

NaV1.2 1.6 channel blocker-1 is a potent inhibitor of NaV1.2 and NaV1.6 channels, exhibiting inhibitory effects on rNaV1.6 and hNaV1.2. This compound can be utilized in the study of generalized epilepsy and movement disorders.

Troriluzole hydrochloride is the third-generation tripeptide precursor of Riluzole and acts as an orally active glutamate modulator. It reduces synaptic glutamate levels while enhancing glutamate uptake. Troriluzole hydrochloride has potential applications for treating Alzheimer's disease and generalized anxiety disorder (GAD).